` SVRA (Savara Inc) vs S&P 500 Comparison - Alpha Spread

SVRA
vs
S&P 500

Over the past 12 months, SVRA has underperformed S&P 500, delivering a return of -41% compared to the S&P 500's 9% growth.

Stocks Performance
SVRA vs S&P 500

Loading
SVRA
S&P 500
Add Stock

Performance Gap
SVRA vs S&P 500

Loading
SVRA
S&P 500
Difference

Performance By Year
SVRA vs S&P 500

Loading
SVRA
S&P 500
Add Stock

Competitors Performance
Savara Inc vs Peers

S&P 500
SVRA
ABBV
AMGN
GILD
VRTX
Add Stock

Savara Inc
Glance View

Market Cap
481.8m USD
Industry
Biotechnology

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The company is headquartered in Austin, Texas and currently employs 22 full-time employees. The company went IPO on 2001-06-25. The firm is focused on rare respiratory diseases. The Company’s lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim an inhaled formulation of recombinant human GM-CSF, is being developed for the treatment of aPAP. Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the build-up of surfactant in the alveoli or air sacs of the lungs.

SVRA Intrinsic Value
2.31 USD
Overvaluation 18%
Intrinsic Value
Price
Back to Top